Skip to main content
Caplight Logo









Rapport Therapeutics

Rapport Therapeutics

Public
Boston, MassachusettsHealthcarehttps://www.rapportrx.com

Rapport Therapeutics is now publicly traded

The data on this page reflects Rapport Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jun 6, 2024

Last Round

Series B

Aug 23, 2023

Total Funding Raised

$424.4M

Company Overview

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for central nervous system (CNS), neurological, and psychiatric disorders. The company's proprietary RAP (receptor-associated proteins) technology platform allows for the specific targeting of receptors in distinct neuroanatomical regions, aiming to create treatments with better efficacy and fewer side effects than existing therapies. Its lead program, RAP-219, is in clinical trials for conditions including drug-resistant focal onset seizures and bipolar mania. Founded in 2022, the company went public in June 2024 and trades on the Nasdaq under the ticker RAPP.

Sector

Healthcare

AI Layer

Non-AI

Keywords

receptor-associated protein (RAP) targeting platformprecision small molecule medicines for CNS disordersTARPγ8 selective small moleculetreatment for drug-resistant focal onset seizuresneuroanatomically specific CNS therapeuticsoral medication for peripheral neuropathic paintherapeutics for bipolar disorderclinical-stage CNS drug developmentα6 nAChR modulators for chronic painα9α10 nAChR modulators for hearing disorders

Rapport Therapeutics Comparables

Compare Rapport Therapeutics with similar companies based on industry and business-model similarity.

Rapport Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tenacia Biotechnology
71%
Newleos Therapeutics
68%
上海赛默罗生物科技有限公司
61%

Rapport Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJun 6, 2024
Series BAug 23, 2023
Series AMar 7, 2023

Key People

Founding team and executive leadership

Troy Ignelzi

Chief Financial Officer

Executive Team

Rapport Therapeutics Investors

Notable investors and investment history

Rapport Therapeutics investors
InvestorRounds
JefferiesIPO
Perceptive AdvisorsSeries B
Fidelity Management & Research CompanySeries B
TD CowenIPO
Invus OpportunitiesSeries A
Logos CapitalSeries B
ARCH Venture PartnersSeries A, Series B, IPO

Rapport Therapeutics Filings

Explore SEC and related filing metadata, where available.

Rapport Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range88
Year Founded2022
Last FundingAug 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?